What are bacteriocins and how can we harness their therapeutic potential?
Antimicrobial resistance (AMR) is one of the biggest threats to global public health, mobilizing researchers and companies to explore non-traditional avenues for treating bacterial infections. Among them is Glox Therapeutics (Glasgow & Oxford, UK) – a company developing precision antibiotics from naturally occurring bacteriocins. Back in February, Glox Therapeutics appointed Michael Murray (left) as Chair of the Board to help guide the commercialization of their precision antibiotic technology. Michael has extensive experience in the biotech and pharma industries. Since 2009, he has been the Principal at Murray International Partners (Edinburgh, UK), where he supports life science companies with commercialization, including...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
